Synapse - Allison Parascondola

Results (27)

First fever between lymphodepletion and day 30 after CAR-T cell therapy: Patterns, origins, and implications in lymphoma patients

Meeting Abstract

Melica, G.; Luna, A.; Fei, T.; Corona, M.; Dahi, P. B.; Fein, J.; Giralt, S. A.; Raj, S.; Landego, I.; Lin, R. J.; more...
Blood (2023)

Fulltext@MSK | Save

Detection of CAR-T cell persistence with digital droplet PCR: Correlation of in vivo expansion with clinical outcomes in a cohort of B-cell lymphoma patients

Meeting Abstract

Cassanello, G.; Borsu, L.; Arcila, M. E.; Yao, J.; Boroujeni, A. M.; Ewalt, M.; Patel, U.; Chan, R.; Gray, B.; Luna De Abia, A.; more...
Blood (2023)

Fulltext@MSK | Save

From widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T- cell therapy: Less is better

Meeting Abstract

Melica, G.; Luna De Abia, A.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Landego, I.; Lin, R. J.; Palomba, M. L.; Parascondola, A.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma

Meeting Abstract

Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Higher CD4+T cell counts after CAR-T in large B-cell lymphomas are significantly associated with better overall survival

Meeting Abstract

Luan, D.; Shouval, R.; Fei, T.; Luttwak, E.; Luna, A.; Corona, M.; Palomba, M. L.; Parascondola, A.; Scordo, M.; Shah, G. L.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy

Meeting Abstract

Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome

Meeting Abstract

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
Blood (2023)

Fulltext@MSK | Save

A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts

Meeting Abstract

Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
Bone Marrow Transplantation (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save